Stay updated with breaking news from Neil Goldenberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today...
This landmark trial, led by Neil Goldenberg, M.D., Ph.D., associate dean for research, and the Clinical Coordinating Center team in the Johns Hopkins All Children’s Institute for Clinical and Translational Research, focused on the emerging pediatric challenge of venous thromboembolism (VTE—also known as “blood clots,” including deep vein thrombosis (DVT) and pulmonary embolism (PE)).
Kids-DOTT trial supports fewer injections for children
Halving the duration of therapy is noninferior to the standard 3 months in patients younger than 21, the Kids-DOTT trial shows.
Goldenberg becomes the Perry Family Endowed Professor in Clinical and Translational Research, and Jallo is the David M. Goldenberg Family Endowed Chair in the Institute for Brain Protection Sciences.